Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARSA | P15289 | 1/20 | 0.32 |
| ▸ | CDC25A | P30304 | 1/20 | 0.32 |
| ▸ | CDC25C | P30307 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24908244 | 1.00 | ARSA (0.32) | ARSACDC25ACDC25CKDM4EMEN1 | |
| SCHEMBL25035773 | 0.97 | ARSA (0.34) | ARSACDC25ACDC25CKDM4EMEN1 | |
| SCHEMBL24908350 | 0.95 | ARSA (0.32) | ARSACDC25ACDC25CKDM4EALDH1A1 | |
| SCHEMBL24908338 | 0.94 | PRKDC (0.31) | ARSACDC25ACDC25CKDM4EMEN1 | |
| SCHEMBL24908189 | 0.94 | PRKDC (0.31) | ARSACDC25ACDC25CKDM4EMEN1 | |
| SCHEMBL24859994 | 0.94 | KDM4E (0.34) | ARSACDC25ACDC25CKDM4EMEN1 | |
| SCHEMBL25035905 | 0.92 | PRKDC (0.32) | ARSACDC25ACDC25CKDM4EMEN1 | |
| SCHEMBL17122590 | 0.90 | ARSA (0.33) | ARSACDC25ACDC25CKMT2A | |
| SCHEMBL24908188 | 0.90 | ARSA (0.30) | ARSACDC25ACDC25C | |
| SCHEMBL24908321 | 0.90 | KDM4E (0.31) | ARSACDC25ACDC25CKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230042023-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-02-09 | — | — | US | disclosed |
| US-20230020436-A1 | NOVEL COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020436-A1 | NOVEL COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS | MRPS22, RER1, EMC2 | ARSA 2350/4885CDC25A 4007/4885CDC25C 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.